Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Genotyping Market by Product (Instruments, Reagents and Kits, Software and Services), by Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others) by Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others) by End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

A00698

Pages: 231

Charts: 68

Tables: 168

Genotyping Market Research, 2033

The global genotyping market size was valued at $16.8 billion in 2023, and is projected to reach $61.6 Billion by 2033, growing at a CAGR of 13.8% from 2024 to 2033. Rise in prevalence of genetic disorders, increase in demand for personalized medicine, and advances in technology, such as next-generation sequencing and polymerase chain reaction (PCR) are the major factors which drives the market growth.

 Key Market Segments

  • By Product
    • Instruments
    • Reagents and Kits
    • Software and Services
  • By Technology
    • PCR
    • Capillary Electrophoresis
    • Microarrays
    • Sequencing
    • Mass Spectrometry
    • Others
  • By Application
    • Pharmacogenomics
    • Diagnostics and Personalized Medicine
    • Agricultural Biotechnology
    • Animal Genetics
    • Others
  • By End User
    • Pharmaceutical and Biopharmaceutical Companies
    • Diagnostics and Research Laboratories
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • QIAGEN 
  • F. Hoffmann-La Roche Ltd
  • Integrated DNA Technologies, Inc.
  • Agilent Technologies, Inc
  • Eurofins Genomics LLC
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • PacBio
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: GENOTYPING MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Instruments

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Reagents And Kits

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Software And Services

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: GENOTYPING MARKET, BY TECHNOLOGY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Technology

    • 5.2. PCR

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Capillary Electrophoresis

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Microarrays

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Sequencing

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Mass Spectrometry

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Others

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: GENOTYPING MARKET, BY APPLICATION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Application

    • 6.2. Pharmacogenomics

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Diagnostics And Personalized Medicine

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Agricultural Biotechnology

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Animal Genetics

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Others

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

  • CHAPTER 7: GENOTYPING MARKET, BY END USER

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By End User

    • 7.2. Pharmaceutical And Biopharmaceutical Companies

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Diagnostics And Research Laboratories

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Others

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

  • CHAPTER 8: GENOTYPING MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product

      • 8.2.3. Market Size and Forecast, By Technology

      • 8.2.4. Market Size and Forecast, By Application

      • 8.2.5. Market Size and Forecast, By End User

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Genotyping Market

        • 8.2.7.1. Market Size and Forecast, By Product
        • 8.2.7.2. Market Size and Forecast, By Technology
        • 8.2.7.3. Market Size and Forecast, By Application
        • 8.2.7.4. Market Size and Forecast, By End User

      • 8.2.8. Canada Genotyping Market

        • 8.2.8.1. Market Size and Forecast, By Product
        • 8.2.8.2. Market Size and Forecast, By Technology
        • 8.2.8.3. Market Size and Forecast, By Application
        • 8.2.8.4. Market Size and Forecast, By End User

      • 8.2.9. Mexico Genotyping Market

        • 8.2.9.1. Market Size and Forecast, By Product
        • 8.2.9.2. Market Size and Forecast, By Technology
        • 8.2.9.3. Market Size and Forecast, By Application
        • 8.2.9.4. Market Size and Forecast, By End User

    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product

      • 8.3.3. Market Size and Forecast, By Technology

      • 8.3.4. Market Size and Forecast, By Application

      • 8.3.5. Market Size and Forecast, By End User

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Genotyping Market

        • 8.3.7.1. Market Size and Forecast, By Product
        • 8.3.7.2. Market Size and Forecast, By Technology
        • 8.3.7.3. Market Size and Forecast, By Application
        • 8.3.7.4. Market Size and Forecast, By End User

      • 8.3.8. Germany Genotyping Market

        • 8.3.8.1. Market Size and Forecast, By Product
        • 8.3.8.2. Market Size and Forecast, By Technology
        • 8.3.8.3. Market Size and Forecast, By Application
        • 8.3.8.4. Market Size and Forecast, By End User

      • 8.3.9. Italy Genotyping Market

        • 8.3.9.1. Market Size and Forecast, By Product
        • 8.3.9.2. Market Size and Forecast, By Technology
        • 8.3.9.3. Market Size and Forecast, By Application
        • 8.3.9.4. Market Size and Forecast, By End User

      • 8.3.10. Spain Genotyping Market

        • 8.3.10.1. Market Size and Forecast, By Product
        • 8.3.10.2. Market Size and Forecast, By Technology
        • 8.3.10.3. Market Size and Forecast, By Application
        • 8.3.10.4. Market Size and Forecast, By End User

      • 8.3.11. UK Genotyping Market

        • 8.3.11.1. Market Size and Forecast, By Product
        • 8.3.11.2. Market Size and Forecast, By Technology
        • 8.3.11.3. Market Size and Forecast, By Application
        • 8.3.11.4. Market Size and Forecast, By End User

      • 8.3.12. Russia Genotyping Market

        • 8.3.12.1. Market Size and Forecast, By Product
        • 8.3.12.2. Market Size and Forecast, By Technology
        • 8.3.12.3. Market Size and Forecast, By Application
        • 8.3.12.4. Market Size and Forecast, By End User

      • 8.3.13. Rest Of Europe Genotyping Market

        • 8.3.13.1. Market Size and Forecast, By Product
        • 8.3.13.2. Market Size and Forecast, By Technology
        • 8.3.13.3. Market Size and Forecast, By Application
        • 8.3.13.4. Market Size and Forecast, By End User

    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product

      • 8.4.3. Market Size and Forecast, By Technology

      • 8.4.4. Market Size and Forecast, By Application

      • 8.4.5. Market Size and Forecast, By End User

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Genotyping Market

        • 8.4.7.1. Market Size and Forecast, By Product
        • 8.4.7.2. Market Size and Forecast, By Technology
        • 8.4.7.3. Market Size and Forecast, By Application
        • 8.4.7.4. Market Size and Forecast, By End User

      • 8.4.8. Japan Genotyping Market

        • 8.4.8.1. Market Size and Forecast, By Product
        • 8.4.8.2. Market Size and Forecast, By Technology
        • 8.4.8.3. Market Size and Forecast, By Application
        • 8.4.8.4. Market Size and Forecast, By End User

      • 8.4.9. India Genotyping Market

        • 8.4.9.1. Market Size and Forecast, By Product
        • 8.4.9.2. Market Size and Forecast, By Technology
        • 8.4.9.3. Market Size and Forecast, By Application
        • 8.4.9.4. Market Size and Forecast, By End User

      • 8.4.10. South Korea Genotyping Market

        • 8.4.10.1. Market Size and Forecast, By Product
        • 8.4.10.2. Market Size and Forecast, By Technology
        • 8.4.10.3. Market Size and Forecast, By Application
        • 8.4.10.4. Market Size and Forecast, By End User

      • 8.4.11. Australia Genotyping Market

        • 8.4.11.1. Market Size and Forecast, By Product
        • 8.4.11.2. Market Size and Forecast, By Technology
        • 8.4.11.3. Market Size and Forecast, By Application
        • 8.4.11.4. Market Size and Forecast, By End User

      • 8.4.12. Thailand Genotyping Market

        • 8.4.12.1. Market Size and Forecast, By Product
        • 8.4.12.2. Market Size and Forecast, By Technology
        • 8.4.12.3. Market Size and Forecast, By Application
        • 8.4.12.4. Market Size and Forecast, By End User

      • 8.4.13. Malaysia Genotyping Market

        • 8.4.13.1. Market Size and Forecast, By Product
        • 8.4.13.2. Market Size and Forecast, By Technology
        • 8.4.13.3. Market Size and Forecast, By Application
        • 8.4.13.4. Market Size and Forecast, By End User

      • 8.4.14. Indonesia Genotyping Market

        • 8.4.14.1. Market Size and Forecast, By Product
        • 8.4.14.2. Market Size and Forecast, By Technology
        • 8.4.14.3. Market Size and Forecast, By Application
        • 8.4.14.4. Market Size and Forecast, By End User

      • 8.4.15. Rest of Asia Pacific Genotyping Market

        • 8.4.15.1. Market Size and Forecast, By Product
        • 8.4.15.2. Market Size and Forecast, By Technology
        • 8.4.15.3. Market Size and Forecast, By Application
        • 8.4.15.4. Market Size and Forecast, By End User

    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product

      • 8.5.3. Market Size and Forecast, By Technology

      • 8.5.4. Market Size and Forecast, By Application

      • 8.5.5. Market Size and Forecast, By End User

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Genotyping Market

        • 8.5.7.1. Market Size and Forecast, By Product
        • 8.5.7.2. Market Size and Forecast, By Technology
        • 8.5.7.3. Market Size and Forecast, By Application
        • 8.5.7.4. Market Size and Forecast, By End User

      • 8.5.8. South Africa Genotyping Market

        • 8.5.8.1. Market Size and Forecast, By Product
        • 8.5.8.2. Market Size and Forecast, By Technology
        • 8.5.8.3. Market Size and Forecast, By Application
        • 8.5.8.4. Market Size and Forecast, By End User

      • 8.5.9. Saudi Arabia Genotyping Market

        • 8.5.9.1. Market Size and Forecast, By Product
        • 8.5.9.2. Market Size and Forecast, By Technology
        • 8.5.9.3. Market Size and Forecast, By Application
        • 8.5.9.4. Market Size and Forecast, By End User

      • 8.5.10. UAE Genotyping Market

        • 8.5.10.1. Market Size and Forecast, By Product
        • 8.5.10.2. Market Size and Forecast, By Technology
        • 8.5.10.3. Market Size and Forecast, By Application
        • 8.5.10.4. Market Size and Forecast, By End User

      • 8.5.11. Argentina Genotyping Market

        • 8.5.11.1. Market Size and Forecast, By Product
        • 8.5.11.2. Market Size and Forecast, By Technology
        • 8.5.11.3. Market Size and Forecast, By Application
        • 8.5.11.4. Market Size and Forecast, By End User

      • 8.5.12. Rest of LAMEA Genotyping Market

        • 8.5.12.1. Market Size and Forecast, By Product
        • 8.5.12.2. Market Size and Forecast, By Technology
        • 8.5.12.3. Market Size and Forecast, By Application
        • 8.5.12.4. Market Size and Forecast, By End User

  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning, 2024

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Illumina, Inc.

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Thermo Fisher Scientific Inc.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. QIAGEN 

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. F. Hoffmann-La Roche Ltd

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Danaher Corporation

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Agilent Technologies, Inc

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Eurofins Genomics LLC

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. Bio-Rad Laboratories, Inc.

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. PacBio

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Integrated DNA Technologies, Inc.

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL GENOTYPING MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL GENOTYPING MARKET FOR INSTRUMENTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL GENOTYPING MARKET FOR REAGENTS AND KITS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL GENOTYPING MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL GENOTYPING MARKET, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL GENOTYPING MARKET FOR PCR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL GENOTYPING MARKET FOR CAPILLARY ELECTROPHORESIS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL GENOTYPING MARKET FOR MICROARRAYS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL GENOTYPING MARKET FOR SEQUENCING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL GENOTYPING MARKET FOR MASS SPECTROMETRY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL GENOTYPING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. GLOBAL GENOTYPING MARKET, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 13. GLOBAL GENOTYPING MARKET FOR PHARMACOGENOMICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 14. GLOBAL GENOTYPING MARKET FOR DIAGNOSTICS AND PERSONALIZED MEDICINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 15. GLOBAL GENOTYPING MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 16. GLOBAL GENOTYPING MARKET FOR ANIMAL GENETICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 17. GLOBAL GENOTYPING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 18. GLOBAL GENOTYPING MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. GLOBAL GENOTYPING MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. GLOBAL GENOTYPING MARKET FOR DIAGNOSTICS AND RESEARCH LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. GLOBAL GENOTYPING MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. GLOBAL GENOTYPING MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 23. NORTH AMERICA GENOTYPING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 24. NORTH AMERICA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 25. NORTH AMERICA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 26. NORTH AMERICA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 27. NORTH AMERICA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. U.S. GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 29. U.S. GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 30. U.S. GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 31. U.S. GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. CANADA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 33. CANADA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 34. CANADA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 35. CANADA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. MEXICO GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 37. MEXICO GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 38. MEXICO GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 39. MEXICO GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 40. EUROPE GENOTYPING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 41. EUROPE GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 42. EUROPE GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 43. EUROPE GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 44. EUROPE GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. FRANCE GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 46. FRANCE GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 47. FRANCE GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 48. FRANCE GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. GERMANY GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 50. GERMANY GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 51. GERMANY GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 52. GERMANY GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. ITALY GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 54. ITALY GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 55. ITALY GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 56. ITALY GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. SPAIN GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 58. SPAIN GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 59. SPAIN GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 60. SPAIN GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 61. UK GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 62. UK GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 63. UK GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 64. UK GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 65. RUSSIA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. RUSSIA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 67. RUSSIA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 68. RUSSIA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 69. REST OF EUROPE GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 70. REST OF EUROPE GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 71. REST OF EUROPE GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 72. REST OF EUROPE GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 73. ASIA-PACIFIC GENOTYPING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 74. ASIA-PACIFIC GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 75. ASIA-PACIFIC GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 76. ASIA-PACIFIC GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 77. ASIA-PACIFIC GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 78. CHINA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 79. CHINA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 80. CHINA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 81. CHINA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 82. JAPAN GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 83. JAPAN GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 84. JAPAN GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 85. JAPAN GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 86. INDIA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 87. INDIA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 88. INDIA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 89. INDIA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 90. SOUTH KOREA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 91. SOUTH KOREA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 92. SOUTH KOREA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 93. SOUTH KOREA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 94. AUSTRALIA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 95. AUSTRALIA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 96. AUSTRALIA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 97. AUSTRALIA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 98. THAILAND GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 99. THAILAND GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 100. THAILAND GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 101. THAILAND GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 102. MALAYSIA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 103. MALAYSIA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 104. MALAYSIA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 105. MALAYSIA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 106. INDONESIA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 107. INDONESIA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 108. INDONESIA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 109. INDONESIA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 111. REST OF ASIA PACIFIC GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 112. REST OF ASIA PACIFIC GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 113. REST OF ASIA PACIFIC GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 114. LAMEA GENOTYPING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 115. LAMEA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 116. LAMEA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 117. LAMEA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 118. LAMEA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 119. BRAZIL GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 120. BRAZIL GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 121. BRAZIL GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 122. BRAZIL GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 123. SOUTH AFRICA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 124. SOUTH AFRICA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 125. SOUTH AFRICA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 126. SOUTH AFRICA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 127. SAUDI ARABIA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 128. SAUDI ARABIA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 129. SAUDI ARABIA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 130. SAUDI ARABIA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 131. UAE GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 132. UAE GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 133. UAE GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 134. UAE GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 135. ARGENTINA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 136. ARGENTINA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 137. ARGENTINA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 138. ARGENTINA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 139. REST OF LAMEA GENOTYPING, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 140. REST OF LAMEA GENOTYPING, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 141. REST OF LAMEA GENOTYPING, BY APPLICATION, 2025-2033 ($MILLION)
  • TABLE 142. REST OF LAMEA GENOTYPING, BY END USER, 2025-2033 ($MILLION)
  • TABLE 143. ILLUMINA, INC.: KEY EXECUTIVES
  • TABLE 144. ILLUMINA, INC.: COMPANY SNAPSHOT
  • TABLE 145. ILLUMINA, INC.: OPERATING SEGMENTS
  • TABLE 146. ILLUMINA, INC.: PRODUCT PORTFOLIO
  • TABLE 147. ILLUMINA, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 148. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 149. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 150. THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
  • TABLE 151. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 152. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 153. QIAGEN : KEY EXECUTIVES
  • TABLE 154. QIAGEN : COMPANY SNAPSHOT
  • TABLE 155. QIAGEN : OPERATING SEGMENTS
  • TABLE 156. QIAGEN : PRODUCT PORTFOLIO
  • TABLE 157. QIAGEN : KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158. F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 159. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 160. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 161. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 162. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 163. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 164. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 165. DANAHER CORPORATION: OPERATING SEGMENTS
  • TABLE 166. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 167. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 168. AGILENT TECHNOLOGIES, INC: KEY EXECUTIVES
  • TABLE 169. AGILENT TECHNOLOGIES, INC: COMPANY SNAPSHOT
  • TABLE 170. AGILENT TECHNOLOGIES, INC: OPERATING SEGMENTS
  • TABLE 171. AGILENT TECHNOLOGIES, INC: PRODUCT PORTFOLIO
  • TABLE 172. AGILENT TECHNOLOGIES, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 173. EUROFINS GENOMICS LLC: KEY EXECUTIVES
  • TABLE 174. EUROFINS GENOMICS LLC: COMPANY SNAPSHOT
  • TABLE 175. EUROFINS GENOMICS LLC: OPERATING SEGMENTS
  • TABLE 176. EUROFINS GENOMICS LLC: PRODUCT PORTFOLIO
  • TABLE 177. EUROFINS GENOMICS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 178. BIO-RAD LABORATORIES, INC.: KEY EXECUTIVES
  • TABLE 179. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 180. BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 181. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 182. BIO-RAD LABORATORIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 183. PACBIO: KEY EXECUTIVES
  • TABLE 184. PACBIO: COMPANY SNAPSHOT
  • TABLE 185. PACBIO: OPERATING SEGMENTS
  • TABLE 186. PACBIO: PRODUCT PORTFOLIO
  • TABLE 187. PACBIO: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 188. INTEGRATED DNA TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 189. INTEGRATED DNA TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 190. INTEGRATED DNA TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 191. INTEGRATED DNA TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 192. INTEGRATED DNA TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOTYPING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL GENOTYPING MARKET
  • FIGURE 3. SEGMENTATION GENOTYPING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN GENOTYPING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGENOTYPING MARKET
  • FIGURE 11. GENOTYPING MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. GENOTYPING MARKET FOR INSTRUMENTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. GENOTYPING MARKET FOR REAGENTS AND KITS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. GENOTYPING MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. GENOTYPING MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 16. GENOTYPING MARKET FOR PCR, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. GENOTYPING MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. GENOTYPING MARKET FOR MICROARRAYS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. GENOTYPING MARKET FOR SEQUENCING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. GENOTYPING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. GENOTYPING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 22. GENOTYPING MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 23. GENOTYPING MARKET FOR PHARMACOGENOMICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 24. GENOTYPING MARKET FOR DIAGNOSTICS AND PERSONALIZED MEDICINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 25. GENOTYPING MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 26. GENOTYPING MARKET FOR ANIMAL GENETICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 27. GENOTYPING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 28. GENOTYPING MARKET SEGMENTATION, BY BY END USER
  • FIGURE 29. GENOTYPING MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 30. GENOTYPING MARKET FOR DIAGNOSTICS AND RESEARCH LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 31. GENOTYPING MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 32. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 33. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 34. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 35. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 36. COMPETITIVE DASHBOARD
  • FIGURE 37. COMPETITIVE HEATMAP: GENOTYPING MARKET
  • FIGURE 38. TOP PLAYER POSITIONING, 2024
  • FIGURE 39. ILLUMINA, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. ILLUMINA, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. ILLUMINA, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. THERMO FISHER SCIENTIFIC INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. QIAGEN : NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. QIAGEN : REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. QIAGEN : REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. DANAHER CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. DANAHER CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. DANAHER CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. AGILENT TECHNOLOGIES, INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. AGILENT TECHNOLOGIES, INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. AGILENT TECHNOLOGIES, INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 57. EUROFINS GENOMICS LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 58. EUROFINS GENOMICS LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 59. EUROFINS GENOMICS LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 60. BIO-RAD LABORATORIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 61. BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 62. BIO-RAD LABORATORIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 63. PACBIO: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 64. PACBIO: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 65. PACBIO: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 66. INTEGRATED DNA TECHNOLOGIES, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 67. INTEGRATED DNA TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 68. INTEGRATED DNA TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Genotyping Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved